Business Wire

Esmark Chairman James P. Bouchard & Martina Roda Donate $25,000 to Aid Ukrainian Refugees in Slovakia, Urge Others to Donate With Additional $25,000 Pledge

Share

Esmark Inc. today announced that Chairman & CEO James P. Bouchard and Martina Roda have made an initial donation of $25,000 USD to aid and support Ukrainians seeking refuge in Košice, Slovakia. They will also match monetary donations made by Americans who support Ukrainian refugees up to an additional $25,000 USD.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220315005141/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Esmark Inc. announced it has donated $25,000 to aid Ukrainian refugees, and it pledges an additional $25,000 in matching contributions. Esmark is a diversified, privately-held, family company with a portfolio of industrial companies with strong roots in the steel industry. The company has a long-standing history of charitable and humanitarian support across the globe, donating more than $10 million over the last 15 years. (Photo: Business Wire)

Bouchard is a former U.S. Steel executive vice president and statutory representative of the Slovak Republic, transforming East Slovakian Ironworks, Košice–now known as U.S. Steel Košice–in Slovakia after U.S. Steel acquired it. Bouchard and Roda’s donation was made on behalf of the former U.S. Steel American and Slovak Commercial teams.

This initial donation was made directly to the City of Košice, a city led by Mayor Ing. Jaroslav Polaček, with whom Esmark, Bouchard and Roda have a long-standing relationship.

“Every day, Ukrainian civilians are arriving in Slovakia to seek shelter, food, safety, and kindness,” said Bouchard. “Providing resources to neighboring countries and cities—like Košice—enables them to help these innocent people during one of the darkest times of their lives.”

According to Reuters, more than 2.6 million Ukrainian civilians—mostly women and children— have fled the country since Russia’s invasion, with 185,000 people arriving in Slovakia seeking refuge.

“We are immensely grateful to Esmark, Mr. Bouchard and Ms. Roda for this generous donation. The funds will be used to continue providing shelter, food and safety to our neighbors fleeing Ukraine,” said Košice City Mayor Ing. Jaroslav Polaček.

“Jim and I remain good friends with many of our former colleagues in Slovakia. They have been keeping us informed of the influx of refugees into Košice, estimating that more than 17,000 refugees have arrived,” said Roda. “On behalf of our friends and former colleagues, we wanted to provide swift support so that they can deliver immediate aid to people in need.”

Esmark and Bouchard have a history of and commitment to helping others in need. Over the last 15 years, more than $10 million has been donated to humanitarian relief and children’s charities.

Bouchard continued, “We will standby for future and additional Košice-Ukrainian relief efforts for families and children.”

HOW TO TAKE ACTION:

Esmark will make an additional donation up to $25,000 USD to the City of Košice, matching monetary contributions made by Americans to help Ukrainian refugees. Donations can be made to any legitimate and verified organization including, but not limited to, UNICEF USA, ActionAid USA, Americares, Mercy Corps. Donors should email a confirmation code/receipt to donations@esmark.com.

About Esmark, Inc.

Esmark, Inc. is a diversified, privately-held family company with a portfolio of industrial companies with strong roots in the steel industry. Over the years, Esmark has diversified its interests and operations into a number of businesses engaged in the industrial and commodity sectors. Esmark (a former publicly traded company on NASDAQ: ESMK) has focused on several key industries including steel services, oil and gas exploration, aviation, real estate, professional services, technology and youth sports development. The company is also an active corporate citizen in the communities it serves, having committed more than $10 million in philanthropic support of a wide range of humanitarian, education, family wellness and youth sports programs in Pennsylvania, Illinois and internationally. www.esmark.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Katie Regan
Director of Communications
Esmark, Inc.
Katie.regan@esmark.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye